

Distinguishing truly recalcitrant prurigo nodularis from poor treatment adherence: a response to treatment-resistant prurigo nodularis [Response to letter]

This article was published in the following Dove Press journal:
Clinical, Cosmetic and Investigational Dermatology

Eric H Kowalski¹
Diana Kneiber¹
Manuel Valdebran²
Umangi Patel¹
Kyle T Amber¹ 

¹Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA;

²Department of Dermatology, University of California-Irvine, Irvine, CA, USA

Dear editor

Kolli et al shed light on a pertinent issue of poor adherence to therapy in the treatment of prurigo nodularis (PN).¹ While our intention was to cover recalcitrance in the sense of medical failure, Kolli et al bring up an extremely valuable point: adherence to therapy is dismal.² Escalation of therapy as a result of poor compliance may result in unintended adverse effects from the more potent systemic therapies delineated in the treatment of PN. Thus, ensuring compliance with the treatment protocol should be a priority.

In our view, PN is most often a phenotypic manifestation of chronic pruritus secondary to a host of diseases. Presumably, the relative adherence to treatment for the underlying cause of the PN, in cases where there is one, has a large role to play in the recalcitrance of the PN. This is perhaps most glaring in the case of atopic dermatitis (AD). AD has been identified to contribute to PN development in nearly 50% of PN patients.³ Assessment of nonadherence, as well as steroid phobia has been well documented in the AD population and almost certainly contributes to the development of clinically deemed recalcitrant PN in this population.^{4,5} Because of the well-established efficacy of topical corticosteroids in the treatment of atopic dermatitis, it is likely that atopic PN would prove more responsive. Thus, “treatment resistant” atopic PN, requires serious consideration of nonadherence. Clinical data on nonadherence in nonatopic PN patients, however, remains undetermined.

Regardless of the primary underlying cause, patients receiving supervised phototherapy in the outpatient setting offer insight into truly recalcitrant PN due to complete adherence. A recent review on phototherapy in treatment of PN showed that in 5 out of 11 studies, patients experienced recalcitrant disease.⁶ Thus, even in a supervised setting where adherence could be monitored, numerous cases were recalcitrant.

Innovation in adherence strategies across a wide spectrum of therapies ideally will result in fewer “treatment-resistant” cases.^{7–9} We agree with Kolli et al, that it remains vital to distinguish between poor adherence and medical failure.

Disclosure

The authors report no conflicts of interest in this communication.

Correspondence: Kyle T Amber
Department of Dermatology, University of Illinois at Chicago,
808 S Wood St, RM377, Chicago, IL
60612, USA
Email ktamber@uic.edu

References

1. Kolli SS, Haidari W, Feldman SR. Treatment-resistant prurigo nodularis [letter]. *Clin Cosmet Investig Dermatol*. In press 2019.
2. Kowalski EH, Kneiber D, Valdebran M, Patel U, Amber KT. Treatment-resistant prurigo nodularis: challenges and solutions. *Clin Cosmet Investig Dermatol*. 2019;12:163–172. doi:10.2147/CCID.S188070
3. Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, Ständer S. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. *J Eur Acad Dermatol Venereol*. 2013;27(5):550–557. doi:10.1111/j.1468-3083.2012.04481.x
4. Bos B, Antonescu I, Osinga H, Veenje S, de Jong K, de Vries TW. Corticosteroid phobia (corticophobia) in parents of young children with atopic dermatitis and their health care providers. *Pediatr Dermatol*. 2019;36(1):100–104. doi:10.1111/pde.13698
5. Patel N, Feldman SR. Adherence in atopic dermatitis. *Adv Exp Med Biol*. 2017;1027:139–159. doi:10.1007/978-3-319-64804-0_12
6. Nakamura M, Koo JY. Phototherapy for the treatment of prurigo nodularis: a review. *Dermatol Online J*. 2016;22(4). pii:13030/qt4b07778z
7. Armstrong AW, Johnson MA, Lin S, Maverakis E, Fazel N, Liu FT. Patient-centered, direct-access online care for management of atopic dermatitis: a randomized clinical trial. *JAMA Dermatol*. 2015;151(2):154–160. doi:10.1001/jamadermatol.2014.2299
8. Cline A, Unrue EL, Collins A, Feldman SR. Adherence to a novel home phototherapy system with integrated features. *Dermatol Online J*. 2019;25(3).pii:13030/qt1rw9f75h
9. Singer HM, Levin LE, Morel KD, Garzon MC, Stockwell MS, Lauren CT. Texting atopic dermatitis patients to optimize learning and eczema area and severity index scores: a pilot randomized control trial. *Pediatr Dermatol*. 2018;35(4):453–457. doi:10.1111/pde.13510

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical, Cosmetic and Investigational Dermatology ‘letters to the editor’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical, Cosmetic and Investigational Dermatology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical, Cosmetic and Investigational Dermatology

Dovepress

Publish your work in this journal

Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access, online journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. This journal is indexed on CAS.

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal>